TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $40.67.

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday. HC Wainwright raised their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.50% of the company's stock.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Sei Investments Co. acquired a new stake in shares of TG Therapeutics during the first quarter worth about $591,000. Russell Investments Group Ltd. increased its stake in TG Therapeutics by 133.5% during the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company's stock worth $796,000 after buying an additional 29,923 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of TG Therapeutics by 10.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 43,283 shares of the biopharmaceutical company's stock worth $651,000 after purchasing an additional 4,120 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of TG Therapeutics in the 1st quarter valued at about $91,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in TG Therapeutics by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company's stock valued at $1,303,000 after purchasing an additional 5,015 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $0.33 during trading hours on Monday, hitting $34.74. 1,663,192 shares of the company traded hands, compared to its average volume of 3,693,376. The firm's 50-day simple moving average is $25.62 and its two-hundred day simple moving average is $21.70. The firm has a market cap of $5.41 billion, a P/E ratio of -357.76 and a beta of 2.19. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 1-year low of $12.30 and a 1-year high of $36.84.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the prior year, the business posted $0.73 earnings per share. The business's revenue for the quarter was down 49.4% compared to the same quarter last year. As a group, analysts forecast that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.